Multiple Myeloma: A Personal Account of My Journey With the Disease and Response to Teclistamab

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jun 7

PMID 38846238

Authors

Mohammad Ahmad

Musa F Zahrani

Ghazi S Alotaibi

Fatimah Alshalati

Ammarah Afzal

Ibrahim N Alrumaih

Rabia Riaz

Muhammad Tayyab

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma (MM) remains an incurable hematologic cancer leading to damage to the bone marrow that causes destructive bone lesions in addition to many other effects. I am a patient with MM who has undergone treatment to date since the diagnosis of this disease in December 2019. This paper reviews the treatments and observations made throughout this period. The salient results of such treatments are discussed in chronological order. During this period, my MM relapsed and then I was introduced to teclistamab treatment. The outcome of teclistamab treatment is quite promising, and I anticipate a longer life at a maintenance dose of this drug with a better quality of life. When writing this article, I am still receiving the teclistamab treatment cycles that maintain a constant normal level of my kappa-free light chain (FLC) and kappa/lambda ratio, with no significant side effects.

Citing Articles

An Unusual Increase in the CD38 Marker Observed in a Multiple Myeloma Patient With t(11;14) Translocation: A Case Report.

Rivera Troia F, Ocasio Villa F Cureus. 2024; 16(7):e63563.

PMID: 39087203 PMC: 11289740. DOI: 10.7759/cureus.63563.

References

Tanenbaum B, Miett T, Patel S . The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Ann Hematol. 2022; 102(1):1-11. PMC: 10888499. DOI: 10.1007/s00277-022-05058-5. View

Dima D, Davis J, Ahmed N, Jia X, Sannareddy A, Shaikh H . Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience. Transplant Cell Ther. 2023; 30(3):308.e1-308.e13. DOI: 10.1016/j.jtct.2023.12.016. View

Yang T, Lin C, Ho C, Huang T, Wu Y, Jhou H . Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review. Life (Basel). 2023; 13(12). PMC: 10744445. DOI: 10.3390/life13122259. View

Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505. PMC: 10587778. DOI: 10.1056/NEJMoa2203478. View

Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View

Rajkumar S . Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; 97(8):1086-1107. PMC: 9387011. DOI: 10.1002/ajh.26590. View

Usmani S, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021; 398(10301):665-674. DOI: 10.1016/S0140-6736(21)01338-6. View

Xu L, Wen C, Xia J, Zhang H, Liang Y, Xu X . Targeted immunotherapy: harnessing the immune system to battle multiple myeloma. Cell Death Discov. 2024; 10(1):55. PMC: 10821908. DOI: 10.1038/s41420-024-01818-6. View

Rajkumar S, Hayman S, Lacy M, Dispenzieri A, Geyer S, Kabat B . Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005; 106(13):4050-3. PMC: 1895238. DOI: 10.1182/blood-2005-07-2817. View

10.

Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V . Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024; 14(1):35. PMC: 10914756. DOI: 10.1038/s41408-024-01003-z. View

11.

Nooka A, Rodriguez C, Mateos M, Manier S, Chastain K, Banerjee A . Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2023; 130(6):886-900. DOI: 10.1002/cncr.35107. View

12.

Kumar S, Dispenzieri A, Lacy M, Gertz M, Buadi F, Pandey S . Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2013; 28(5):1122-8. PMC: 4000285. DOI: 10.1038/leu.2013.313. View

13.

Palumbo A, Anderson K . Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60. DOI: 10.1056/NEJMra1011442. View

14.

Cowan A, Green D, Kwok M, Lee S, Coffey D, Holmberg L . Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022; 327(5):464-477. DOI: 10.1001/jama.2022.0003. View

15.

Richardson P, Blood E, Mitsiades C, Jagannath S, Zeldenrust S, Alsina M . A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006; 108(10):3458-64. PMC: 1895441. DOI: 10.1182/blood-2006-04-015909. View

16.

Kang C . Teclistamab: First Approval. Drugs. 2022; 82(16):1613-1619. PMC: 9646474. DOI: 10.1007/s40265-022-01793-1. View

17.

Pan D, Richter J . Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody. Cancer Manag Res. 2023; 15:741-751. PMC: 10368105. DOI: 10.2147/CMAR.S372237. View

18.

DAgostino M, Bertamini L, Oliva S, Boccadoro M, Gay F . Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. Cancers (Basel). 2019; 11(12). PMC: 6966449. DOI: 10.3390/cancers11122015. View